ANI Pharmaceuticals (ANIP) Lifted to “B” at TheStreet

TheStreet upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a c+ rating to a b rating in a report issued on Thursday, November 16th.

Several other brokerages also recently issued reports on ANIP. Canaccord Genuity initiated coverage on shares of ANI Pharmaceuticals in a research report on Monday, July 31st. They set a buy rating and a $60.00 price objective for the company. BidaskClub downgraded shares of ANI Pharmaceuticals from a hold rating to a sell rating in a research report on Saturday, August 5th. ValuEngine upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, November 4th. Finally, Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating and set a $71.00 price target for the company in a research report on Tuesday, November 7th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $68.25.

ANI Pharmaceuticals (NASDAQ:ANIP) traded down $1.42 during trading on Thursday, reaching $69.25. The company had a trading volume of 141,487 shares, compared to its average volume of 137,515. ANI Pharmaceuticals has a fifty-two week low of $42.23 and a fifty-two week high of $74.70. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. The company has a market capitalization of $806.28, a PE ratio of 21.10 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The business had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter last year, the company posted $1.09 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 25.0% on a year-over-year basis. sell-side analysts anticipate that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

Several institutional investors have recently modified their holdings of the stock. Prudential Financial Inc. boosted its position in ANI Pharmaceuticals by 1.4% during the first quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock valued at $697,000 after acquiring an additional 200 shares during the last quarter. California Public Employees Retirement System boosted its position in ANI Pharmaceuticals by 20.0% during the first quarter. California Public Employees Retirement System now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $1,099,000 after acquiring an additional 3,700 shares during the last quarter. Thrivent Financial For Lutherans boosted its position in ANI Pharmaceuticals by 5.1% during the first quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $224,000 after acquiring an additional 220 shares during the last quarter. Vanguard Group Inc. boosted its position in ANI Pharmaceuticals by 5.7% during the first quarter. Vanguard Group Inc. now owns 441,226 shares of the specialty pharmaceutical company’s stock valued at $21,845,000 after acquiring an additional 23,806 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in ANI Pharmaceuticals by 4.6% during the first quarter. Geode Capital Management LLC now owns 64,378 shares of the specialty pharmaceutical company’s stock valued at $3,187,000 after acquiring an additional 2,816 shares during the last quarter. 55.05% of the stock is currently owned by institutional investors.

WARNING: “ANI Pharmaceuticals (ANIP) Lifted to “B” at TheStreet” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/04/ani-pharmaceuticals-inc-anip-raised-to-b-at-thestreet.html.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply